CA
NZ
UK
AU
IND
US
…
Pliant Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing integrin-based therapeutics for the treatment of solid tumors. The company's lead product candidate is the PLN-101095, an oral, small molecule dual inhibitor of avß8 and avß1 integrins that is in Phase 1a/1b for the treatment of solid tumors. It is also developing drug discovery platform comprising proprietary library of over 15,000 integrin binding molecules, focusing on integrin-based target-mediated drug delivery. Pliant Therapeutics, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
Pliant Therapeutics is a clinical-stage biopharmaceutical company developing oral small-molecule therapies targeting fibrotic diseases through integrin modulation. Long-term growth drivers include clinical trial progress, potential regulatory approvals and expansion into multiple-organ fibrosis indications that could support commercialization. Investors may find the company attractive because it appears positioned to address high unmet medical need with differentiated candidates.
Major investment risks include clinical trial failure, the need for additional financing and strong competition in fibrosis therapeutics.
Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Income before tax | -149.34M | -210.30M | -161.34M | -123.32M | -19.71M |
| Net income | -149.34M | -210.30M | -161.34M | -121.50M | -17.91M |
| Selling general administrative | 47.22M | 59.05M | 57.93M | 39.95M | 27.56M |
| Gross profit | -1.70M | -2.12M | 1.58M | 9.69M | 7.57M |
| Reconciled depreciation | 1.70M | 2.12M | 1.83M | 1.82M | 1.53M |
| Ebit | -146.78M | -207.28M | -160.07M | -127.20M | -21.52M |
| Ebitda | -145.09M | -205.16M | -158.23M | -122.53M | -19.99M |
| Depreciation and amortization | 1.70M | 2.12M | 1.84M | 4.67M | 1.53M |
| Non operating income net other | - | - | - | 3.88M | 0.27M |
| Operating income | -150.07M | -228.37M | -184.15M | -127.20M | -19.99M |
| Other operating expenses | 150.07M | 228.37M | 185.72M | 136.88M | 27.56M |
| Interest expense | 2.56M | 3.02M | 1.27M | 0.79M | 0.27M |
| Interest income | 11.42M | 21.09M | 20.48M | 4.67M | 0.27M |
| Net interest income | 8.86M | 18.06M | 19.22M | 3.88M | 0.27M |
| Income tax expense | - | - | 1.67M | -1.82M | -1.81M |
| Total revenue | 0.00M | 0.00M | 1.58M | 9.69M | 7.57M |
| Total operating expenses | 148.38M | 228.37M | 185.72M | 136.88M | 27.56M |
| Cost of revenue | 1.70M | 2.12M | 1.84M | - | - |
| Total other income expense net | 0.73M | 18.06M | 22.81M | 3.88M | 0.27M |
| Net income from continuing ops | -149.34M | -210.30M | -155.29M | -123.32M | -97.26M |
| Net income applicable to common shares | - | - | - | -123.32M | -19.71M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Total assets | 225.23M | 396.95M | 512.15M | 350.61M | 221.22M |
| Other current assets | 4.68M | 4.24M | 8.26M | 7.06M | 6.76M |
| Total liab | 44.02M | 92.87M | 38.58M | 37.27M | 22.16M |
| Total stockholder equity | 181.21M | 304.08M | 473.58M | 313.34M | 199.06M |
| Other current liab | 14.44M | 26.72M | 22.68M | 19.88M | 11.99M |
| Common stock | 0.01M | 0.01M | 0.01M | 0.01M | 0.00M |
| Capital stock | 0.01M | 0.01M | 0.01M | 0.01M | 0.00M |
| Retained earnings | -859.40M | -710.05M | -499.75M | -338.41M | -215.09M |
| Other assets | - | - | 0.00M | 0.39M | 0.84M |
| Cash | 45.45M | 71.19M | 63.23M | 33.69M | 51.66M |
| Total current liabilities | 16.36M | 33.22M | 28.52M | 23.91M | 16.83M |
| Net debt | -16.34M | -11.00M | -51.86M | -17.87M | -44.47M |
| Short term debt | 1.45M | 0.54M | 1.32M | 2.46M | 1.87M |
| Short long term debt total | 29.11M | 60.19M | 11.37M | 15.81M | 7.19M |
| Other stockholder equity | 1040.61M | 1013.81M | 972.97M | 653.71M | 414.35M |
| Property plant equipment | - | - | - | 4.49M | 10.94M |
| Total current assets | 196.45M | 362.26M | 505.50M | 340.31M | 209.44M |
| Net tangible assets | - | - | - | 313.34M | 199.06M |
| Short term investments | 145.50M | 284.54M | 431.01M | 297.50M | 148.93M |
| Net receivables | 0.82M | 2.30M | 3.00M | 2.07M | 2.08M |
| Long term debt | - | 30.21M | 10.05M | 9.93M | - |
| Accounts payable | 0.48M | 5.96M | 4.53M | 1.58M | 2.97M |
| Accumulated other comprehensive income | -0.01M | 0.32M | 0.34M | -1.96M | -0.20M |
| Common stock total equity | - | - | - | 0.01M | 0.00M |
| Retained earnings total equity | - | - | - | -338.41M | -215.09M |
| Non currrent assets other | 3.77M | 1.92M | 0.39M | 0.39M | 0.84M |
| Non current assets total | 28.78M | 34.69M | 6.65M | 10.30M | 11.77M |
| Capital lease obligations | 29.11M | 29.98M | 1.32M | 5.89M | 7.19M |
| Long term debt total | - | - | - | 9.93M | - |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Investments | 134.51M | 140.34M | -138.91M | -148.44M | 75.65M |
| Change to liabilities | - | - | - | 6.55M | 3.59M |
| Total cashflows from investing activities | 134.29M | 140.34M | -127.01M | -150.20M | 73.70M |
| Net borrowings | -32.27M | 19.91M | 0.00M | 9.85M | 9.85M |
| Total cash from financing activities | -31.70M | 23.12M | 274.40M | 226.85M | 2.53M |
| Change to operating activities | - | - | - | 5.55M | -1.25M |
| Net income | -149.34M | -210.30M | -161.34M | -123.32M | -97.26M |
| Change in cash | -25.74M | 7.95M | 31.03M | -17.98M | 0.78M |
| Begin period cash flow | 72.67M | 64.72M | 33.68M | 51.66M | 50.88M |
| End period cash flow | 46.93M | 72.67M | 64.72M | 33.68M | 51.66M |
| Total cash from operating activities | -128.34M | -155.50M | -116.36M | -94.63M | -75.44M |
| Issuance of capital stock | 0.57M | 3.21M | 275.07M | 217.56M | 2.98M |
| Depreciation | 1.70M | 2.12M | 1.84M | 1.82M | 1.53M |
| Other cashflows from investing activities | 0.15M | - | - | - | - |
| Change to account receivables | - | 0.00M | 1.98M | 0.01M | 7.28M |
| Sale purchase of stock | - | - | - | 215.64M | 2.53M |
| Other cashflows from financing activities | -31.70M | 19.91M | -0.85M | 9.29M | -0.46M |
| Change to netincome | - | - | - | 22.60M | 10.44M |
| Capital expenditures | 0.37M | 3.85M | 0.92M | 1.76M | 1.95M |
| Change receivables | - | - | - | 0.01M | 7.28M |
| Cash flows other operating | - | - | - | -0.49M | -1.02M |
| Cash and cash equivalents changes | - | - | - | -17.98M | 0.78M |
| Change in working capital | -15.94M | 9.09M | 1.25M | 4.22M | 6.92M |
| Stock based compensation | 26.23M | 37.63M | 44.48M | 22.60M | 10.44M |
| Other non cash items | 9.02M | 5.96M | -2.60M | 0.05M | 2.93M |
| Free cash flow | -128.71M | -159.35M | -117.28M | -96.39M | -77.40M |
Sector: Healthcare Industry: Biotechnology
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| PLRX Pliant Therapeutics Inc |
-0.01 1.25% |
0.80 | - | - | 3071.82 | 0.49 | 1376.69 | -2.54 |
| NVO Novo Nordisk A/S |
1.09 2.72% |
41.41 | 41.58 | 31.15 | 2.13 | 32.99 | 2.11 | 4.70 |
| VRTX Vertex Pharmaceuticals Inc |
3.78 0.69% |
550.87 | 30.22 | 24.27 | 10.36 | 6.50 | 9.99 | 24.66 |
| REGN Regeneron Pharmaceuticals Inc |
15.61 1.73% |
919.96 | 29.07 | 20.12 | 7.57 | 3.82 | 6.95 | 19.42 |
| ARGNF argenx SE |
- -% |
900.30 | 45.77 | 31.25 | 13.84 | 7.12 | 11.38 | 36.06 |
Pliant Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing integrin-based therapeutics for the treatment of solid tumors. The company's lead product candidate is the PLN-101095, an oral, small molecule dual inhibitor of avß8 and avß1 integrins that is in Phase 1a/1b for the treatment of solid tumors. It is also developing drug discovery platform comprising proprietary library of over 15,000 integrin binding molecules, focusing on integrin-based target-mediated drug delivery. Pliant Therapeutics, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.
331 Oyster Point Boulevard, South San Francisco, CA, United States, 94080
650 481 6770
49
| Name | Title | Year Born |
|---|---|---|
| Dr. Bernard Coulie M.B.A., M.D., MBA, Ph.D. | Pres, CEO & Director | 1966 |
| Dr. Keith Lamont Cummings M.B.A., M.D. | Chief Financial Officer | 1977 |
| Mr. Mike Ouimette | Gen. Counsel & Corp. Sec. | 1973 |
| Mr. Johannes P. Hull | Chief Bus. Officer | 1975 |
| Dr. Éric Lefebvre M.D. | Chief Medical Officer | 1964 |
| Dr. Rik Derynck | Scientific Founder & Member of Scientific Advisory Board | NA |
| Mr. Dean Sheppard M.D. | Scientific Founder & Member of Scientific Advisory Board | NA |
| Mr. Bill DeGrado Ph.D. | Scientific Founder & Member of Scientific Advisory Board | NA |
| Mr. Hal Chapman M.D. | Scientific Founder & Member of Scientific Advisory Board | NA |
| Mr. Craig D. Muir | Interim Chief Technology Officer | NA |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.
Download a free report with stock ideas and industry insights for general information.
Download Free Report Now →
Basic Materials
+1.88%
Communication Services
+1.14%
Consumer Cyclical
+1.04%
Consumer Defensive
+0.57%
Energy
+0.50%
Financial Services
+0.81%
Financials
+0.24%
Healthcare
+1.35%
Industrials
+1.54%
Real Estate
+0.24%
Technology
+2.32%
Utilities
+0.48%
Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.
Portfolio
Watchlist
-4.40%
Please wait processing your request...